HIMS Hims Hers Health Inc
Company Analysis
Latest News
Hims & Hers pivots to peptides, targeting longevity market after GLP-1 scrutiny
Hims & Hers Health Inc. is expanding into peptides and wellness products, according to a report from The Washington Post. CEO Andrew Dudum plans to enter the...
Hims & Hers Issues $402.5 Million in 0.00% Convertible Senior Notes Due 2032
Hims & Hers Health, Inc. announced the issuance of $402.5 million in aggregate principal amount of 0.00% Convertible Senior Notes due 2032. The total amount...
🟢 HIMS is trading 4% up today on its generic semaglutide launch in Canada
HIMS is trading 4% up today at $23.96 following the launch of its generic semaglutide weight-loss offering in Canada. • The move marks the company's first...
Hims & Hers debuts generic semaglutide in Canada, targeting high treatment costs
Hims & Hers Health is launching a generic version of semaglutide for eligible customers in Canada. This medication contains the active ingredient found in...
Hims & Hers Completes $350 Million Convertible Notes Offering
Hims & Hers Health Inc. completed an upsized private offering of $350 million in convertible senior notes. The notes carry a 0.00% interest rate and mature...
Hims & Hers Prices Upsized $350M Convertible Notes Offering to Fund Expansion and AI
Hims & Hers Health, Inc. announced the pricing of an upsized private offering of $350 million in 0.00% convertible senior notes due 2032. The offering was...
Hims & Hers Upsizes $350 Million Offering, Targets Global Expansion
Hims & Hers Health, Inc. priced an upsized $350 million offering of convertible senior notes. The notes reach maturity in 2032. The company increased the deal...
Hims & Hers Raises Another $300 Million in Convertible Debt — But Can a Company Already Bleeding Cash Afford to Dilute Its Way to Growth?
Shares tumbled 7.8% to $23.09 this morning after Hims & Hers announced a $300 million convertible senior notes offering due 2032 — its second major debt raise...
🔴 HIMS is trading 8% down today after announcing a $300 million convertible notes offering
HIMS is trading 7.82% down at $23.09 after announcing a $300 million convertible senior notes offering due 2032. • The company plans to use the proceeds to...
🔴 HIMS is trading 4.3% down today on $300 million convertible notes offering
HIMS is trading 4.3% down at $23.98 after announcing plans to issue $300 million of convertible senior notes due 2032. • Proceeds are intended to fund...
🔴 HIMS is trading 4.3% down today on plans for a $300 million convertible notes offering
HIMS is trading at $23.98 (4.3% down) in pre-market after the company announced its intention to offer $300 million in convertible senior notes due 2032. •...
🟢 HIMS is trading 4.2% up today on rebound from multi-day pullback
HIMS is trading at $25.25 (4.2% up) as shares bounce following a sharp multi-day pullback earlier this week. • Traders appear to be reassessing the recent...
🔴 HIMS is trading 6.6% down today on Q1 earnings miss and branded GLP-1 margin concerns
HIMS is trading at $23.39 (-6.55%), extending a sharp post-earnings decline following yesterday's -14.1% drop. The company reported Q1 revenue of $608.1M,...
🔴 HIMS is trading 13.18% down today on Q1 earnings miss and margin contraction
HIMS is trading at $25.30 (-13.18%) following a Q1 2026 earnings miss and a sharp swing to a quarterly loss. • Revenue reached $608.1M against the $616.84M...
🔴 HIMS is trading 16% down today after Q1 earnings miss and strategic shift to GLP-1 drugs
HIMS is trading at $24.38 (-16%) in pre-market following a Q1 2026 earnings miss and a strategic pivot toward lower-margin branded GLP-1 medications. • The...
🔴 HIMS is trading 10.1% down today after missing Q1 revenue estimates amid GLP-1 shift
HIMS is trading at $26.19 (-10.1%) in after-hours trading after the company missed Q1 2026 revenue estimates despite raising its full-year guidance. • Revenue...
Hims & Hers Missed Earnings Badly — Can a Guidance Raise and a Novo Nordisk Deal Rescue a Stock That Just Lost 6.8%?
Shares shifted sharply after Hims & Hers Health posted a first quarter that fell short on virtually every line that matters to Wall Street. Revenue came in at...
Hims & Hers first quarter 2026 revenue and EPS miss estimates amid a strategic shift to branded GLP-1s.
Hims & Hers reported first quarter 2026 revenue of $608.1 million, a 4% increase year-over-year, and a net loss per share of $0.40. Both figures fell short of...
🟢 HIMS is trading 5% up today ahead of Q1 earnings and weight-loss category updates
HIMS is trading at $29.73 (+5.18%) as investors position ahead of its Q1 2026 earnings report, scheduled for release after the market close on May 11. •...
🟢 HIMS is trading 4% up today ahead of Q1 earnings and weight-loss updates
HIMS is trading at $29.47 (+4.24%) ahead of its Q1 2026 earnings report and highly anticipated updates regarding its weight-loss category. • Analysts project...